A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
Eun Joo Kang(Korea University), KK Lee(Chungbuk National University), Yoon Ji Choi(Korea University Medical Center), Yu Jung Kim(Seoul National University Bundang Hospital), Woo Kyun Bae(Chonnam National University), S.I. Lee(Korea University), So Yeon Oh(Pusan National University Yangsan Hospital), Hee Kyung Ahn(Samsung Medical Center), Yaewon Yang(Chungbuk National University), I. Kim(Inje University Haeundae Paik Hospital), Han Suk Ryu(Cancer Research Institute), Sang-Ho Lee(Wooridul Hospital), Yong Jae Lee(National Cancer Center), Tae Min Kim(Seoul National University Hospital), Seungtaek Lim(Yonsei University), M-J Ahn(Samsung Medical Center), H-C Jeung(Yonsei University), Kang Hyun Park(Korea University)
Cited by 10
Related Papers
Histone H3 Methylation by Set2 Directs Deacetylation of Coding Regions by Rpd3S to Suppress Spurious Intragenic Transcription
|Cell|2005|1.3k
Quantitative Interaction Proteomics and Genome-wide Profiling of Epigenetic Histone Marks and Their Readers
|Cell|2010|815
Distinct functional domains in emerin bind lamin A and DNA-bridging protein BAF
|Journal of Cell Science|2001|343
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
|JAMA Oncology|2021|289
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
|Journal of the Korean Gastric Cancer Association|2023|285